Curis, Inc..
CRIS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. The company's pipeline includes drug candidates targeting various signaling pathways involved in tumor growth and survival. Curis partners with ot...Show More
Better Health for All
-10
Curis, Inc. is entirely devoted to health improvement, with its product portfolio focused on developing drug candidates for cancer treatment. Clinical trials for emavusertib and CA-4948 have shown positive results, including significant tumor burden reduction and objective responses in patients with various cancers.
1
The company's revenue of $10.9 million in 2024 and $10.0 million in 2023 is primarily from royalties on Erivedge®, a cancer drug, with no evidence of revenue from products with negative health impacts for over two years.
2
The company publicly lists its clinical trials on clinicaltrials.gov and details potential benefits and risks, demonstrating exceptional risk transparency.
3
Research and Development expenses were $8.5 million in Q1 2025 and $38.6 million in 2024.
4
Given the company's net loss of $10.6 million in Q1 2025 and $43.4 million in 2024, R&D spending represents a significant portion of its total expenditure, indicating a strong investment in health innovation.
5
Curis has been granted Orphan Drug Designation in both the US and EU for PCNSL, which can limit competition and potentially impact accessibility, aligning with substantial patent flexibility in lower-income countries.
6
The company states that clinical trials are conducted according to ethical guidelines and emphasizes a commitment to diversity in trials, indicating excellent ethical standards.
7
Fair Money & Economic Opportunity
0
Curis, Inc. is a biotechnology company focused on the development and commercialization of drug candidates for cancer treatment. The provided articles detail the company's financing activities, financial performance, and clinical trial updates. There is no evidence in the articles to suggest that Curis, Inc. operates as a financial institution or offers any lending, insurance, or other financial services to consumers or underserved populations. Therefore, no KPIs under the 'Fair Money & Economic Opportunity' value can be assessed based on the evidence provided.
Fair Pay & Worker Respect
-10
The company's overall employee rating on Indeed.com is 3.1 out of 5 stars (equivalent to 62/100), with a culture rating of 2.8 out of 5 stars (56/100).
1
This places the worker engagement score around 60/100.
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned across the provided articles.
2
Employee reviews offer mixed opinions, with some praising "great benefits" and "flexible" work arrangements, while others criticize management, lack of support, and poor work-life balance.
3
The company's employee count was 34 in 2024, down from 49 in 2023.
4
Fair Trade & Ethical Sourcing
0
No evidence available to assess Curis, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Curis, Inc. on Honest & Fair Business.
Kind to Animals
-60
The company's animal testing protocols and procedures are reviewed and approved by an Institutional Animal Care and Use Committee (IACUC).
1
However, the company used a mouse model for collagen-induced arthritis and systemic inflammation studies, indicating reliance on animal testing.
2
The company used between 25,000 and 50,000 animals annually in testing, specifically mice, and there is no transparent reduction target for this volume.
No War, No Weapons
0
No evidence available to assess Curis, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative environmental data for CRIS.US (Curis, Inc.) was found in the provided articles.
1
Information pertaining to "C.H.G Cyprus Healthcare Group Ltd Operating as: Curis Network" was identified as belonging to a different entity and was therefore not used for this assessment. All articles directly referencing CRIS.US explicitly state that sustainability data is currently unavailable for the company across all relevant metrics.
2
Respect for Cultures & Communities
0
The provided articles do not contain any specific quantitative data or concrete facts related to CRIS.US's performance on the 'Respect for Cultures & Communities' ethical value.
1
The articles are from 'curis-consulting.com' and explicitly state that no relevant data for CRIS.US or cultural respect/community engagement is provided.
2
Safe & Smart Tech
0
The company's privacy policy states that users have rights to access, correct, delete, transfer, restrict, and object to data processing, and provides contact information for exercising these rights.
1
Data is retained only as necessary for stated purposes and is removed or pseudonymized when no longer needed, in accordance with applicable data protection laws.
2
The company also mentions compliance with GDPR and has a designated European Data Protection Officer (EDPO).
3
Zero Waste & Sustainable Products
0
No evidence available to assess Curis, Inc. on Zero Waste & Sustainable Products.